The Role and Mechanisms of Lipoproteins in Cancer
DOI:
https://doi.org/10.54097/6tmzx409Keywords:
Cancer, Lipids, Oxidative Stress, MetabolismAbstract
As the primary contributor to disease-related mortality worldwide, cancer demands the implementation of predictive risk stratification systems to enable early therapeutic engagement. Epidemiological studies confirm that pre-symptomatic detection through biomarker panels reduces cancer-specific mortality by 22-45% across major malignancies. This research systematically evaluates the mechanistic contributions and pathophysiological roles of circulating lipoproteins, specifically focusing on the dichotomous effects of high-density lipoprotein (HDL)-mediated cholesterol efflux and low-density lipoprotein (LDL)-driven pro-tumorigenic signaling in malignant transformation. By conducting a comprehensive literature review, this study delineates the molecular pathways of cholesterol biosynthesis and intracellular trafficking, elucidates its mechanistic role in tumor proliferation and metastasis, and critically evaluates the emerging evidence for hypolipidemic agents as adjunctive cancer therapeutics. Comprehensive analysis suggests that blood lipids and lipoproteins may influence cancer development through insulin resistance, inflammation, and oxidative stress pathways.
Downloads
References
[1] Luo, Jie et al. “Mechanisms and regulation of cholesterol homeostasis.” Nature reviews. Molecular cell biology vol. 21,4 (2020): 225-245. doi:10.1038/s41580-019-0190-7.
[2] Jung, Eujene et al. “Serum Cholesterol Levels and Risk of Cardiovascular Death: A Systematic Review and a Dose-Response Meta-Analysis of Prospective Cohort Studies.” International journal of environmental research and public health vol. 19,14 8272. 6 Jul. 2022, doi:10.3390/ ijerph 19148272.
[3] Casula, Manuela et al. “HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role.” Cells vol. 10,8 1869. 23 Jul. 2021, doi:10.3390/cells10081869.
[4] Patel, Kush K, and Khosrow Kashfi. “Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.” Biochemical pharmacology vol. 196 (2022): 114654. doi:10. 1016/j.bcp.2021.114654.
[5] Ren, Liwen et al. “Apolipoproteins and cancer.” Cancer medicine vol. 8,16 (2019): 7032-7043. doi:10.1002/cam4.2587.
[6] Lee, Kyuwan et al. “The Impact of Obesity on Breast Cancer Diagnosis and Treatment.” Current oncology reports vol. 21,5 41. 27 Mar. 2019, doi:10.1007/s11912-019-0787-1.
[7] Li, Changkun et al. “Systematic review and meta-analysis suggest that dietary cholesterol intake increases risk of breast cancer.” Nutrition research (New York, N.Y.) vol. 36,7 (2016): 627-35. doi:10.1016/j. nutres.2016.04.009.
[8] Guy, C T et al. “Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.” Molecular and cellular biology vol. 12,3 (1992): 954-61. doi:10.1128/mcb.12.3.954-961.1992.
[9] Lin, Elaine Y et al. “Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.” The American journal of pathology vol. 163,5 (2003): 2113-26. doi:10.1016/S0002-9440 (10) 63568-7.
[10] Cleary, M P et al. “Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice.” International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity vol. 28,8 (2004): 956-62. doi:10. 1038/ sj.i jo. 0802664.
[11] Ding, Xiao et al. “The role of cholesterol metabolism in cancer.” American journal of cancer research vol. 9,2 219-227. 1 Feb. 2019.
[12] Hryniewicz-Jankowska, Anita et al. “The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer.” Experimental biology and medicine (Maywood, N.J.) vol. 244,13 (2019): 1053-1061. doi:10.1177/ 1535370 219870771.
[13] Haga, Raquel B, and Anne J Ridley. “Rho GTPases: Regulation and roles in cancer cell biology.” Small GTPases vol. 7,4 (2016): 207-221. doi:10.1080/ 21541248. 2016. 1232 583.
[14] Molnár, G et al. “Role of prenylation in the interaction of Rho-family small GTPases with GTPase activating proteins.” Biochemistry vol. 40,35 (2001): 10542-9. doi:10. 1021/ bi01 1158e.
[15] Morel, Anne-Pierre et al. “A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.” Nature medicine vol. 23,5 (2017): 568-578. doi: 10. 1038/ nm.4323.
[16] Montero, Joan et al. “Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.” Cancer research vol. 68,13 (2008): 5246-56. doi:10.1158/0008-5472. CAN-07-6161.
[17] Garcia-Ruiz, Carmen et al. “MITOCHONDRIAL CHOLESTEROL AND CANCER.” Seminars in cancer biology vol. 73 (2021): 76-85. doi:10.1016/j. semcancer. 2020. 07.014.
[18] Inoue, Manabu et al. “High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages.” Scientific reports vol. 8,1 6736. 30 Apr. 2018, doi:10.1038/s41598-018-24233-1.
[19] Guo, Deliang et al. “Targeting SREBP-1-driven lipid metabolism to treat cancer.” Current pharmaceutical design vol. 20,15 (2014): 2619-26. doi:10.2174/ 138161281131999 90486.
[20] Siemianowicz, K et al. “Serum LDL cholesterol concentration and lipoprotein electrophoresis pattern in patients with small cell lung cancer.” International journal of molecular medicine vol. 5,1 (2000): 55-7. doi:10.3892/ijmm.5.1.55.
[21] Sottero, Barbara et al. “Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.” Medicinal research reviews vol. 35,5 (2015): 968-1031. doi:10.1002/med.21349.
[22] Deng, Chang-Feng et al. “Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.” Frontiers in oncology vol. 12 803473. 16 Feb. 2022, doi: 10. 3389/ fonc.2022.803473.
[23] Balzan, Silvana, and Valter Lubrano. “LOX-1 receptor: A potential link in atherosclerosis and cancer.” Life sciences vol. 198 (2018): 79-86. doi: 10.1016/j.lfs.2018.02.024.
[24] Hale, James S et al. “Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression.” Stem cells (Dayton, Ohio) vol. 32,7 (2014): 1746-58. doi:10.1002/ stem. 1716.
[25] Diakowska, Dorota et al. “Circulating Oxidized Low-Density Lipoproteins and Antibodies against Oxidized Low-Density Lipoproteins as Potential Biomarkers of Colorectal Cancer.” Gastroenterology research and practice vol. 2015 (2015): 146819. doi:10.1155/2015/146819.
[26] Hu, Pengcheng et al. “Low-Density Lipoprotein Cholesterol and Prostate Cancer: A Retrospective Study.” Archivos espanoles de urologia vol. 77,3 (2024): 229-234. doi:10. 56434/ j.arch.esp.urol.20247703.30.
[27] Mogilenko, Denis A et al. “PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells.” Biochemical and biophysical research communications vol. 402,3 (2010): 477-82. doi: 10.1016/j.bbrc.2010.10.053.
[28] Ren, Liwen et al. “Apolipoproteins and cancer.” Cancer medicine vol. 8,16 (2019): 7032-7043. doi:10.1002/cam4.2587.
[29] Cedó, Lídia et al. “ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.” Scientific reports vol. 6 36387. 3 Nov. 2016, doi:10.1038/srep36387.
[30] Nowak, Christoph, and Johan Ärnlöv. “A Mendelian randomization study of the effects of blood lipids on breast cancer risk.” Nature communications vol. 9,1 3957. 27 Sep. 2018, doi:10.1038/s41467-018-06467-9.
[31] Khattab, Mahmoud A et al. “Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma.” Annals of hepatology vol. 11,4 (2012): 487-94.
[32] Patel, P S et al. “Alterations in plasma lipid profile patterns in head and neck cancer and oral precancerous conditions.” Indian journal of cancer vol. 41,1 (2004): 25-31.
[33] Eroglu, Muzaffer et al. “Enhanced HDL-cholesterol-associated anti-oxidant PON-1 activity in prostate cancer patients.” The Kaohsiung journal of medical sciences vol. 29,7 (2013): 368-73. doi: 10.1016/j.kjms.2012.11.004.
[34] Kato, S et al. “Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.” Journal of cellular and molecular medicine vol. 14,5 (2010): 1180-93. doi:10.1111/ j. 1582-4934.2009.00771.x.
[35] Menter, David G et al. “Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.” PloS one vol. 6,12 (2011): e28813. doi:10.1371/ journal. pone. 0028813.
[36] Kodach, Liudmila L et al. “Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway.” Gut vol. 60,11 (2011): 1544-53. doi:10.1136/gut.2011.237495.
[37] Mei, Zubing et al. “Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals.” International journal of cancer vol. 140,5 (2017): 1068-1081. doi:10. 1002/ ijc. 30526].
[38] Lamb, Yvette N. “Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.” American journal of cardiovascular drugs: drugs, devices, and other interventions vol. 20,4 (2020): 381-392. doi:10.1007/s40256-020-00421-1.
[39] He, Jianming et al. “NPC1L1 knockout protects against colitis-associated tumorigenesis in mice.” BMC cancer vol. 15 189. 27 Mar. 2015, doi:10.1186/s12885-015-1230-0.
[40] Solomon, Keith R et al. “Ezetimibe is an inhibitor of tumor angiogenesis.” The American journal of pathology vol. 174,3 (2009): 1017-26. doi:10.2353/ajpath.2009.080551.
[41] Pelton, Kristine et al. “Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo.” The American journal of pathology vol. 184,7 (2014): 2099-110. doi: 10.1016/j.ajpath.2014.03.006.
[42] Ribas, Vicent et al. “Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC.” Cancers vol. 13,16 4091. 13 Aug. 2021, doi:10.3390/cancers13164091.
[43] Masko, Elizabeth M et al. “Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model.” The Prostate vol. 77,5 (2017): 446-457. doi:10.1002/pros.23282.
[44] Kim, Nam Hoon, and Sin Gon Kim. “Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction.” Diabetes & metabolism journal vol. 44,2 (2020): 213-221. doi:10.4093/ dmj. 2020.0001.
[45] Hunt, Sharon A et al. “ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary.” The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation vol. 21,2 (2002): 189-203. doi:10.1016/ s1053-2498(01)00776-8.
[46] Tan, Yan et al. “PPAR-α Modulators as Current and Potential Cancer Treatments.” Frontiers in oncology vol. 11 599995. 23 Mar. 2021, doi:10.3389/fonc.2021.599995.
[47] Chowdhury, Partha S et al. “PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti-PD-1 Therapy.” Cancer immunology research vol. 6,11 (2018): 1375-1387. doi: 10.1158/ 2326-6066.CIR-18-0095.
[48] Park, Jiyoung et al. “Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours.” EMBO molecular medicine vol. 5,6 (2013): 935-48. doi: 10. 1002/ emmm.201202006.
[49] Khandekar, Melin J et al. “Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.” Proceedings of the National Academy of Sciences of the United States of America vol. 115,3 (2018): 561-566. doi:10.1073/ pnas. 1717776115.
[50] Rochel, Natacha et al. “Recurrent activating mutations of PPARγ associated with luminal bladder tumors.” Nature communications vol. 10,1 253. 16 Jan. 2019, doi: 10. 1038/ s41467-018-08157-y.
[51] Saez, E et al. “Activators of the nuclear receptor PPARgamma enhance colon polyp formation.” Nature medicine vol. 4,9 (1998): 1058-61. doi:10.1038/2042.
[52] Makhmudova, Umidakhon et al. “Phytosterols and Cardiovascular Disease.” Current atherosclerosis reports vol. 23, 11 68. 1 Sep. 2021, doi:10.1007/s11883-021-00964-x.
[53] Blanco-Vaca, Francisco et al. “Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials.” Current medicinal chemistry vol. 26,37 (2019): 6735-6749. doi:10.2174/0929867325666180607093111.
[54] Tantamango-Bartley, Yessenia et al. “Vegetarian diets and the incidence of cancer in a low-risk population.” Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 22,2 (2013): 286-94. doi: 10.1158/1055-9965.EPI-12-1060.
[55] Mendilaharsu, M et al. “Phytosterols and risk of lung cancer: a case-control study in Uruguay.” Lung cancer (Amsterdam, Netherlands) vol. 21,1 (1998): 37-45. doi:10.1016/s0169-5002(98)00044-0.
[56] Castagna, M et al. “Tumor-promoting phorbol diesters inhibit in vitro antibody synthesis.” Cancer letters vol. 8,4 (1980): 365-71. doi:10.1016/0304-3835(80)90154-8.
[57] Liu, Siyuan et al. “The potential role of transcription factor sterol regulatory element binding proteins (SREBPs) in Alzheimer's disease.” Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 180 (2024): 117575. doi: 10.1016/j.biopha.2024.117575.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
